US-listed pharmaceuticals company Merck to spin off Organon after acquisition
Organon, a women’s healthcare-focused drugs developer about to be spun off from US-listed pharmaceuticals company Merck, has agreed to acquire Alydia Health for up to $240m. Organon will pay $215m upfront plus a $25m contingent milestone payment. Fifty million dollars of the upfront payment will be paid prior to the spinoff of Organon expected in…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.